A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial

Inclusion Criteria: * • Male sex * 18 - 50 years of age * Hypogonadism following observational period of a minimum of 12 weeks since AAS discontinuation OR hypogonadism with a urine sample negative for AAS analyses at screening visit: plasma total testosterone ≤ 10 nmol/L AND featuring at least one symptom of male hypogonadism using IIEF in terms of erectile function (IIEF: Q1 - Q5 + Q15; total score \< 26) and/or sexual desire (IIEF: Q11 + Q12; total \< 7) (1) and/or ADAM questionnaire (YES to three questions other than question 1 and 7) and/or regular use of medical treatment for erectile dysfunction. * Motivation for permanent AAS cessation Exclusion Criteria: * Established cardiovascular disease * Established diabetes of any kind 384 * Congenital hypogonadal conditions (cryptorchidism, Klinefelter's disease, Kallmann's disease etc.) * Previous established hypogonadal conditions due to other causes than illicit use of AAS * Current or previous treatment with testosterone on other indication than AAS-induced male hypogonadism * Abnormal puberty development (small testes, late or absent pubic hairing, late or absent deepening of voice, etc.) * Current or previous pituitary diseases including pituitary tumors * Current or previous tumors of the hypothalamus * Current or former testicular cancer * Current or previous prostate cancer * Current or previous breast cancer * Other cancers unless complete remission ≥ 5 year * Other concomitant dise…